5-Alpha Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.

Niamh Doherty Christopher R Cardwell Peter Murchie Christopher Hill Laurent Azoulay Blánaid M Hicks

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2023)

The findings of this study indicate that 5-alpha reductase inhibitors are unlikely to reduce kidney or bladder cancer risk.

Keyphrases

benign prostatic hyperplasia
lower urinary tract symptoms
spinal cord injury
urinary tract
middle aged